Skip to main content
Terug
Watch Compare

VYNE Therapeutics Inc.

Datakwaliteit: 100%
VYNE
Nasdaq Manufacturing Chemicals
€ 0,61
▼ € 0,00 (-0,41%)
Marktkapitalisatie: 20,66 M
Prijs
€ 0,62
Marktkapitalisatie
20,66 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Revenue declined -55,67% annually over 5 years
Debt/Equity of 0,00 — conservative balance sheet
Negative free cash flow of -33,12 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 69,44%

Groei

Revenue Growth (5Y)
-55,67%
Onder sectorgemiddelde (1,82%)
Revenue (1Y)13,77%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-63,80%
Onder sectorgemiddelde (-53,47%)
ROIC-56,62%
Net Margin-4646,14%
Op. Margin-5219,12%

Veiligheid

Debt / Equity
0,00
Onder sectorgemiddelde (0,30)
Current Ratio7,60
Interest CoverageN/A

Waardering

PE (TTM)
-0,78
Boven sectorgemiddelde (-1,48)
P/B Ratio0,53
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -0,8 -1,5
P/B 0,5 1,6
ROE % -63,8 -53,5
Net Margin % -4646,1 -41,5
Rev Growth 5Y % -55,7 1,8
D/E 0,0 0,3

Koersdoel Analisten

1 analist
Hold
Huidig
€ 0,61
+227.9%
Koersdoel
€ 2,00
€ 2,00
€ 2,00
€ 2,00
Vooruitzicht
Forward K/W -0,37
Forward WPA -€ 1,65
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 1,65
-€ 1,65 – -€ 1,65
 0,0 1
FY2026 -€ 1,10
-€ 1,10 – -€ 1,10
 233.330,0 1

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 0,23 -€ 0,11 +52,2%
Q32025 -€ 0,13 -€ 0,17 -30,8%
Q22025 -€ 0,22 -€ 0,13 +41,8%
Q12025 -€ 0,29 -€ 0,20 +31,0%

All Fundamental Metrics
Growth
Revenue Growth (1Y) 13,77% Revenue Growth (3Y) 15,95%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -55,67% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 570.000,0 Net Income (TTM) -26,48 M
ROE -63,80% ROA -52,37%
Gross Margin N/A Operating Margin -5219,12%
Net Margin -4646,14% Free Cash Flow (TTM) -33,12 M
ROIC -56,62% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,00 Current Ratio 7,60
Interest Coverage N/A Asset Turnover 0,01
Working Capital 38,51 M Tangible Book Value 38,88 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,78 Forward P/E N/A
P/B Ratio 0,53 P/S Ratio 36,25
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -160,33%
Market Cap 20,66 M Enterprise Value -1,39 M
Per Share
EPS (Diluted TTM) -0,62 Revenue / Share 0,02
FCF / Share -0,99 OCF / Share -0,99
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 125,08%
SBC-Adj. FCF -36,14 M Growth Momentum 69,44

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 570.000,0 501.000,0 424.000,0 477.000,0 14,76 M
Net Income -26,48 M -39,83 M -28,45 M -23,21 M -73,33 M
EPS (Diluted) -0,62 -0,93 -2,78 -7,28 1,42
Gross Profit — — — — —
Operating Income -29,75 M -43,64 M -29,26 M -34,30 M -68,03 M
EBITDA — — — — —
R&D Expenses 19,24 M 30,95 M 16,31 M 18,39 M 24,96 M
SG&A Expenses — — — 16,39 M 54,48 M
D&A 23.000,0 4.000,0 0,0 72.000,0 109.000,0
Interest Expense — — — 0,0 5,61 M
Income Tax 4.000,0 4.000,0 0,0 13.000,0 -448.000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 30,16 M 66,91 M 97,69 M 40,76 M 67,05 M
Total Liabilities 2,40 M 14,82 M 8,95 M 9,35 M 18,41 M
Shareholders' Equity 27,77 M 52,09 M 88,74 M 31,20 M 48,64 M
Total Debt 0,0 0,0 0,0 0,0 0,0
Cash & Equivalents 24,03 M 19,93 M 30,62 M 30,91 M 42,25 M
Current Assets 30,01 M 64,44 M 95,96 M 38,28 M 63,19 M
Current Liabilities 2,40 M 14,82 M 7,54 M — 18,41 M